Equity Details
Price & Market Data
Price: $91.31
Daily Change: +$3.92 / 4.29%
Daily Range: $85.65 - $91.49
Market Cap: $6,257,712,128
Daily Volume: 655,093
Performance Metrics
1 Week: -1.08%
1 Month: 5.18%
3 Months: -11.24%
6 Months: -8.96%
1 Year: 54.85%
YTD: -14.70%
About Rhythm Pharmaceuticals, Inc. (RYTM)
Your go-to source for Rhythm Pharmaceuticals, Inc. (RYTM) market data. Current price: 91.31, daily change: +$3.92 / 4.29%. Market cap: 6,257,712,128. All essential performance metrics are here, from 1-month to 1-year.
Company Details
Employees: 414
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.